DALLAS, TX (June 27, 2022) —  Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that CEO and Co-Founder Sulagna Bhattacharya has been named a winner of Ernst & Young’s Entrepreneur Of The Year® 2022 Central Plains Award.

Entrepreneur Of The Year is one of the preeminent competitive business awards for entrepreneurs and leaders of high-growth companies who think big to succeed. An independent panel of judges selected Ms. Bhattacharya based on her entrepreneurial spirit, purpose, growth, and impact, among other core contributions and attributes.

“I am honored to be named a winner in this competition by such a prestigious business organization alongside this dynamic group of business leaders making a difference in their respective fields,” said Ms. Bhattacharya. “This distinction is truly a win for the team at Nanoscope and reflects the passion and ingenuity we bring to work every day. It also underscores the tremendous progress we are making in the clinic advancing our groundbreaking platform of optogenetic therapies to restore vision in people suffering from retinitis pigmentosa and other retinal diseases.”

Entrepreneur Of The Year celebrates entrepreneurs through regional and national awards programs in more than 145 cities in over 60 countries. As a Central Plains award winner, Ms. Bhattacharya will now be considered by the National judges for the Entrepreneur Of The Year 2022 National Awards.

For over 35 years, EY US has celebrated the unstoppable entrepreneurs who are building a more equitable, sustainable and prosperous world for all. Entrepreneur Of The Year Award winners have exclusive, ongoing access to the experience, insight and wisdom of fellow alumni and other members of the entrepreneurial community in over 60 countries — all supported by vast EY resources.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The Company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients. MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Dallas, TX (June 13, 2022) — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that CEO and Co-Founder Sulagna Bhattacharya will give a Company overview and a clinical update on the Company’s pipeline during the BIO International Convention, being held June 13-16, 2022, in San Diego, CA. The presentation, titled “Pioneering A New Wave of Optogenetic Therapeutics for Vision Restoration,” will take place on June 14, at 4:15 PM PT in Company Presentation Theater 3.

“We will highlight our Multi-Characteristic Opsin gene therapy candidate, MCO-010, which is part of our optogenetics platform for vision restoration in people blinded by retinitis pigmentosa and other retinal diseases,” said Ms. Bhattacharya.

“This is an exciting time for the Company as we advance our clinical programs and expect multiple clinical milestones for MCO-010 over the next 12-months. In the first quarter of 2023, we anticipate reporting both topline Phase 2b RESTORE data results for MCO-010 in patients with retinitis pigmentosa, as well as 6-month data from our open label Phase 2 STARLIGHT trial for patients with Stargardt disease,” continued Ms. Bhattacharya.

Ms. Bhattacharya presently serves on the board of directors of BIO.  She is also a member of the BIO sub-committee for capital formation, advocating for public policy beneficial to small cap and private biotech companies. She will be involved in BIO Board of Directors activities throughout the week.  Additionally, Nanoscope executive team members will be available for meetings to discuss partnering and strategic opportunities.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients. MCO-010 has received FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

PR Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

DALLAS, Texas (June 6, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced two  presentations featuring the Company’s clinical development of optogenetic gene therapy for vision restoration in retinitis pigmentosa (RP) patients at the upcoming 45^th Annual Meeting of The Macula Society, to be held June 8-11, 2022, in Berlin, Germany.

“The two abstract presentations will highlight our Multi-Characteristic Opsin gene therapy, MCO-010, for RP, which is part of our optogenetics platform for vision restoration of people blinded by retinal diseases regardless of gene mutations,” said Sulagna Bhattacharya, CEO of Nanoscope. “Our multi-site, double blind, sham-controlled Phase 2b trial in RP patients is fully enrolled with results expected in Q1 2023. We are also initiating a multi-site Phase 2 trial of MCO-010 for Stargardt macular degeneration”

Details for the presentations are as follows:

Title: 52 Week Safety and Efficacy of Optogenetic Therapy for Vision Restoration in Inherited Retinal Degeneration Patients
Session: Inherited Retinal Diseases
Presenter: Sai Chavala, MD, Professor, TCU School of Medicine, Fort Worth, TX. Dr. Chavala is a Nanoscope Scientific and Clinical Advisor.
Date and Time: Wednesday, June 8, 2022, from 6:06 p.m. – 6:52 p.m. CEST

Title: Design and Development of novel endpoints for Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study of Multi-Characteristic Opsin enabled vision restoration in patients with advanced retinitis pigmentosa
Session: Inherited Retinal Diseases
Presenter: Victor Hugo Gonzalez, MD, Valley Retina Institute, McAllen, TX. Dr. Gonzalez is a Nanoscope Scientific and Clinical Advisor.
Date and Time: Saturday, June 11, 2022, from 7:37 – 8:42 a.m. CEST

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing site restoring optogenetic therapies for millions of patients suffering from retinal degenerative diseases.  A Phase 1/2a open label trial (NCT04919473) of Nanoscope’s lead product, MCO-010 in advanced RP patients (n=11), demonstrated a favorable safety profile and several patients experienced restoration of vision to a level sufficient to resume activities of daily living. A multicenter, randomized, double-masked, sham-controlled Phase 2b clinical trial of MCO-010 in RP patients (NCT04945772) is fully enrolled (N=27) and in follow-up. Primary data are expected in H1-2023. The company is initiating Phase-2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.

Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Media Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Dallas, TX (May 25, 2022) — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that Naveed Shams MD, PhD, and Thomas Ciulla MD, both of whom have extensive executive leadership experience at pioneering ophthalmology companies, will serve as advisors to the Company’s Board and Management.

“We are extremely pleased to have these distinguished leaders join our team of advisors. Their deep experience and long list of accomplishments in the ophthalmology space will play a key role in providing guidance to support our clinical and corporate strategy. We look forward to leveraging their expertise as we advance of Nanoscope’s groundbreaking platform of optogenetic therapies,” said Nanoscope’s Co-Founder and CEO, Sulagna Bhattacharya.

“By delivering light-sensitive molecules into retinal cells, Nanoscope is advancing a unique gene therapy approach to restoring vision in people suffering from various inherited retinal degenerative diseases, including Retinitis Pigmentosa (RP), Stargardt, and dry AMD,” said Dr. Shams. “Their unique and creative approach to treating blinding eye diseases and strong clinical data to date shows potential to revolutionize how we treat retinal degenerative diseases and improve patient outcomes. I hope to contribute to the rapid advancement of this platform as the Company completes its ongoing Phase 2b study in RP and looks to rapidly expand into other indications.”

“Multi-Characteristic Opsin, or MCOs, have the potential to address all forms of retinal degeneration and are applicable for patients suffering from complete or partial damage to the retina,” said Dr. Ciulla. “Nanoscope has already begun to demonstrate the tremendous potential of this approach, including extraordinary efficacy and good tolerability in severely visually impaired individuals. I look forward to working with their world-class team in seeing the potential of this approach fully elucidated in the clinic.”

Dr. Shams was most recently the Chief Science Officer at ProQR Therapeutics and previously served as President and CEO of Santen Inc, and Global Head of R&D at Santen Pharmaceuticals, a global ophthalmology company, for over a decade. He has over 25 years of global drug development experience across start-ups and large multinationals, including Novartis and Genentech/Roche. At Genentech, Dr. Shams helped to establish the Ophthalmic Clinical R&D Group and led the development of Lucentis^® through approval. Prior to joining industry Dr. Shams was on the Faculty at the Department of Ophthalmology, Harvard Medical School. Dr. Shams holds an MD from Dow Medical College and a PhD in microbiology/immunology from the University of South Carolina. He also completed a fellowship in wound healing and corneal transplantation at Harvard University.

Dr. Ciulla has 25 years of executive management, clinical research and academic leadership experience. He has served as Chief Medical Officer since 2018 and also Chief Development Officer since 2020 at Clearside Biomedical, which pioneered the development of the first FDA-approved suprachoroidal therapy (Xipere®). At Spark Therapeutics, he led medical strategy through approval and commercialization of Luxturna® (voretigene), the first FDA-approved gene therapy for a hereditary retinal disease, which involved novel functional vision endpoints, complex genetic testing paradigms, and new administration procedures. Prior to Spark, he served as VP-Clinical Strategy at Ophthotech (now Iveric Bio), where he contributed to the design of the successful Phase 2/3 trial of Zimura®in Geographic Atrophy (GA). He holds a BA in chemistry from Harvard University, an MD from University of California, San Francisco, Medical School and an MBA from Indiana University. He completed residency at Harvard Medical School, retina fellowship at Tufts Medical School, and is a board-certified ophthalmologist and retina specialist.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1, 2023. The company has also initiated a Phase 2 trial of MCO therapy in Stargardt patients. MCO-010 has received FDA orphan drug designations for RP and Stargardt. The pipeline also includes therapy for GA.

Investor Contact:
Kimberly Minarovich, Sam Martin
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

DALLAS, May 13, 2022  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced four presentations on the Company’s clinical development and research programs at the 25^th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), May 16-19, 2022, at the Walter E. Washington Convention Center in Washington, D.C. The international convention (in-person and virtual) attracts thousands of scientists, patient advocates, physicians, and government officials.

“Nanoscope will be highlighting its MCO-010 clinical gene therapy program that demonstrated vision restoration in people blinded by retinal diseases as well as pioneering nonviral laser delivery of MCO-020 gene therapy for geographic atrophy and optogenetic modulation of neurological disorders,” said Sulagna Bhattacharya, CEO of Nanoscope.

ASGCT will feature two presentations on MCO-010 and two on MCO-020 (all times are U.S. EDT):

Monday, May 16, 3:45 pm – 5:30 pm, Salon H
Synthetic Nanoparticle-Based Gene Transfer oral abstract presentation
In Vivo Spatially Targeted Nonviral Optical Delivery of Genes in Mice to NHPs, Monday, May 16, 4:15 – 4:30
pm – Sanghoon Kim, Ph.D.

Monday, May 16, 5:30 pm – 6:30 pm, Hall D
Ophthalmic and Auditory Diseases poster session
Optogenetic Gene Therapy for Treatment of Inherited Retinal Disorders in a Gene Agnostic Manner [Board No.
M-174] – Subrata Batabyal, Ph.D.

Neurologic Diseases I poster session
Optogenetic Modulation of the Central Nervous System for Pain [Board No. M-152] – Darryl Narcisse, M.D.

Tuesday, May 17, 5:30 pm – 6:30 pm, Hall D
Gene and Cell Therapy Trials in Progress poster session
AAV Intravitreal Optogenetic Therapy for Vision Restoration in Patients with Severe Retinal Dystrophy [Board
No. Tu-306] – Samarendra Mohanty, Ph.D.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies to give sight to millions of patients suffering from retinal degenerative diseases. Nanoscope’s lead product, MCO-010, is an investigational AAV gene therapy designed to restore functional vision to patients with severe vision loss due to retinal degeneration. In a Phase 1/2a open label trial (NCT04919473) of MCO-010 in patients with advanced RP (n=11), MCO-010 demonstrated a favorable safety profile and several patients experienced restoration of vision to a level sufficient to resume activities of daily living. A multicenter, randomized, double-masked, sham-controlled Phase 2b clinical trial of MCO-010 for treatment of RP (NCT04945772) is fully enrolled (N=27) and in follow-up. Primary data are expected in H1-2023. The company is initiating Phase-2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

DALLAS, Texas (April 26, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic therapies for treatment of retinal degenerative diseases, today announced four presentations on the Company’s preclinical and clinical research in retinitis pigmentosa (RP) and Stargardt macular degeneration at the Association for  Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, being held May 1 – 4, 2022, in Denver, Colorado.

“We are excited to showcase the breadth and depth of our gene therapy programs from creating disease models to mutation-agnostic gene therapy, and novel instrumentation for assessing retinal function and functional vision in pre-clinical models and in the clinic,” said Sulagna Bhattacharya, CEO of Nanoscope “Our presentations highlight our efforts to address outer retinal degenerative diseases with the goal of bringing relief to the millions of patients worldwide.”

Nanoscope presentations at ARVO-2022:

AAV-carried MCO Optogenetic Therapy for the Treatment of Inherited Retinal Disorders

Presenter: Subrata Batabyal, Ph.D.
Date/Time: May 1, 2022; 12:15 PM – 2:15 PM MDT
Location: A0047, Poster Hall

Double-masked, Randomized, sham-controlled, Multicenter Phase 2b study of Multi-Characteristic Opsin enabled vision restoration in patients with advanced retinitis pigmentosa: Design and Development of novel endpoints

Presenter: Samarendra Mohanty, Ph.D.
Date/Time: May 2, 2022; 12:30 PM – 2:30 PM MDT
Location: F0040, Poster Hall

Establishing a novel preclinical laser-induced model for regenerative therapies of the outer retina

Presenter: Silvia Aparicio Domingo, MS.
Date/Time: May 2, 2022; 1:00 PM – 3:00 PM MDT
Location: F0399, Poster Hall

OCT-guided variable-spot ERG enabled spatially resolved measurements to assess retinal function in a selected and integrated region

Presenter: Sanghoon Kim, Ph.D.
Date/Time: May 4, 2022; 11:08 AM – 11:25 PM MDT
Location: 4EF, Mile High Ballroom

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies to give sight to millions of patients suffering from retinal degenerative diseases. Nanoscope’s lead product, MCO-010, is an investigational AAV gene therapy designed to restore functional vision to patients with severe vision loss due to retinal degeneration. In a Phase 1/2a open label trial of MCO-010 in patients with advanced RP (n=11), MCO-010 demonstrated a favorable safety profile and several patients experienced restoration of vision to a level sufficient to resume activities of daily living.  A multicenter, randomized, double-masked, sham-controlled Phase 2b clinical trial of MCO-010 for treatment of RP (NCT04945772) is fully enrolled (N=27) and in follow-up. Primary data are expected in H1-2023. The company will begin Phase-2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

DALLAS, April 18, 2022 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal diseases, today announced Aaron Osborne, MBBS, was appointed Chief Medical Officer and Chief Development Officer. He is joined by recent hires Anil Lalwani, MS, MBA, Vice President of CMC and Quality, and Jared Stephens, PhD, Vice President of Strategy and BD.

“We are excited to welcome these experienced biopharmaceutical executives,” said Sulagna Bhattacharya, Nanoscope CEO. “They will play integral roles in developing our optogenetic gene therapies to restore vision in millions of people blinded by retinal diseases.”

Dr. Osborne has over 20 years’ experience in ophthalmology. Most recently, he served as Chief Medical Officer at Adverum while previously he held clinical development and medical affairs roles of increasing responsibility at Genentech, Alcon, Novartis and Bayer. Dr. Osborne earned his medical degree at University College London, before becoming a member of the Royal College of Ophthalmologists in 2004. Subsequently he began his career as a drug developer and has since successfully advanced multiple retinal therapeutic programs.

“I am passionate about advancing transformative therapies that have the potential to dramatically improve people’s lives,” Dr. Osborne said. “And that is precisely what Nanoscope is doing with its novel optogenetics approach. I’m thrilled to be joining this talented team in its mission of restoring vision to patients with advanced retinal diseases.”

Mr. Lalwani joined from AbbVie and has 25 years’ experience in CMC, quality and regulatory affairs in the biopharmaceutical industry. He holds an MSc in Biotechnology from UPenn, and an MBA in Health Care from University of Miami.

Dr. Stephens leads strategy and business development for Nanoscope Therapeutics.  Prior to joining Nanoscope, he served as Director of Strategy, Search & Evaluation for GE Healthcare and leadership roles at Absci and Bionano. He holds a PhD in Cell and Molecular Biology from UC-Irvine.

About Nanoscope Therapeutics Inc.
Nanoscope’s Multi-Characteristic Opsin (MCO) mutation-agnostic gene therapy platform is designed to restore vision in patients blinded by retinal degenerative diseases. The company is conducting a multi-site randomized and sham-controlled Phase 2b clinical trial for retinitis pigmentosa (NCT04945772). Results are expected in Q1 2023. The company also expects to begin Phase 2 clinical trials for Stargardt macular degeneration in Q2-2022. MCO therapy received orphan drug designations from the FDA for RP and Stargardt.

Dan Eramian
Opus Biotech Communications
danieleramian@comcast.net
425-306-8716

DALLAS, April 4, 2022 / — Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced expansion of its Clinical and Scientific Advisory Board to include three newly appointed members.

“These distinguished physicians and scientists are joining to advise our company in developing groundbreaking optogenetic gene therapies to restore vision in patients with macular degeneration,” said Nanoscope Co-Founder and CEO Sulagna Bhattacharya.

The new members are:

• Arshad Khanani, MD, MA, Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, Reno; and Clinical Associate Professor at the University of Nevada, Reno School of Medicine.
• Eleonora Lad, M.D., Ph.D., Associate Professor of Ophthalmology, Duke University Medical Center; Director of the Ophthalmology Clinical Research Unit, and Director of Grading, Duke Reading Center
• Charles Wykoff, M.D., Ph.D., Director of Research at Retina Consultants of Texas and the Greater Houston Retina Research Foundation; Chairman of the Research and Clinical Trials Subcommittee, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital.

They join current advisory board members David Boyer, M.D.; Sai Chavala, M.D.; Steven Gray, Ph.D.; Jeff Heier, M.D.; Peter Kaiser, M.D.; Stephen Kaminsky, Ph.D.; Vittorio Porciatti, DSc; SriniVas Sadda, M.D.; Michael Singer, M.D.; Stephen Tsang, M.D, Ph.D.; Paul Yang, M.D., Ph.D.; and Thomas Yorio, Ph.D.

“I am excited to work with our advisors to accelerate the pipeline into broader patient populations with geographic atrophies,” said Nanoscope Co-Founder and President Samarendra Mohanty.

Nanoscope’s Multi-Characteristic Opsin (MCO) gene therapy platform is designed to restore vision in patients blinded by retinal degenerative diseases regardless of genetic mutations. The company is conducting a Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for its lead asset targeting retinitis pigmentosa (RP) (NCT04945772). Topline results are expected in Q1 2023. The company also expects to begin Phase 2 clinical trials of a follow-on asset targeting Stargardt macular degeneration in H1-2022. MCO therapy has received orphan drug designations from the FDA for RP and Stargardt.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies to restore sight in millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s pipeline includes therapies for RP, Stargardt, other Inherited Retinal Degenerations, and Geographic Atrophies. For more information visit: https://nanostherapeutics.com/

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Dallas, TX (March 28, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies to treat retinal degenerative diseases, today announced that Co-founder, President, and Chief Scientific Officer, Samarendra Mohanty, Ph.D., will make a presentation at the Advancing Gene Therapy 2022 Summit to be held March 28 – 30, 2022, at the Hilton Boston Woburn in Woburn, MA.

Dr. Mohanty’s presentation, titled “Pioneering New Wave for Optogenetic Therapeutics for Vision Restoration,” will be on Wednesday, March 30 (2:15 pm – 2:40 pm ET) and is part of the summit’s Session on Gene Therapy for Ocular Diseases.

Nanoscope is developing a proprietary Multi-Characteristic Opsin (MCO) gene therapy platform to reprogram healthy retinal cells, making them photosensitive for restoring vision in people blinded by retinal degenerative diseases regardless of genetic mutations. MCO therapy involves a one-time intravitreal injection given in a medical office setting. The company’s lead asset, MCO-010, is in development for retinitis pigmentosa (RP).  Nanoscope also has follow-on programs in Stargardt and dry age-related macular degeneration (dry-AMD) and has received orphan drug designations from the FDA for RP and Stargardt.

A completed Phase 1/2a study of MCO-010 in 11 RP patients demonstrated that MCO therapy is safe and offers improved quality of life (significant functional vision improvement) in advanced RP patients. The company’s multicenter, randomized, double-masked, sham-controlled Phase 2b clinical trial (NCT04945772), launched in June 2021, is fully enrolled with topline results expected in Q1 2023. Nanoscope has also received FDA IND clearance for Ph2 clinical trials of MCO-010 for Stargardt macular degeneration. The trials are expected to begin in H1-2022.

The Advancing Gene Therapy 2022 Summit is organized by the Biogate Scientific Center and features an international group of experts from pharmaceutical and biotech companies, academia, and government institutions. The Summithighlights the challenging field of gene therapeutic approaches, including advances in development and manufacturing as well as quality control methods and regulatory aspects.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies to restore sight in millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics-based retinal gene therapies for patients with RP, Stargardt disease, and dry-AMD. For more information visit https://nanostherapeutics.com/

Contact:

Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

DALLAS, Feb. 17, 2022  — Nanoscope Therapeutics Inc., a late clinical-stage ocular gene therapy company, today announced the election of CEO Sulagna Bhattacharya to the Biotechnology Innovation Organization (BIO) Emerging Companies Section Governing Board.

Washington D.C.-based BIO is the world’s largest Biotechnology advocacy organization representing companies, academic institutions, and local biotechnology centers across the U.S. and globally. Bhattacharya joins other industry leaders to set BIO’s policy and priorities that ultimately facilitate new life-changing therapies.

“I am thrilled by this opportunity to further integrate with fellow industry thought leaders and excited to help shape the future of therapeutics together with them,” said Bhattacharya. “BIO has been a key growth driver for biotech and scores of new therapies that companies like mine are developing for countless patients with unmet medical needs. I look forward to contributing to the vital roles BIO plays.”

“We are very pleased to have Sulagna join our board,” said Dr. Michelle McMurry-Heath, President & CEO of BIO. “She will bring a unique and valuable perspective to our work, and her leadership will help ensure we are shaping and advancing the policy priorities needed to improve the lives of patients around the globe.”

Nanoscope’s optogenetic gene therapy platform restores vision in patients blinded by Inherited Retinal Diseases (IRD) like retinitis pigmentosa (RP) and Stargardt macular degeneration. MCO therapy utilizes a single intravitreal injection in a doctor’s office. The platform has received FDA orphan drug designations for RP and Stargardt disease.

Nanoscope’s lead asset (MCO-010) is fully enrolled for the multicenter, double-masked,  randomized Ph2b trial in RP patients  (top-line results expected Q1 2023). The company recently received IND clearance from FDA for a Ph2 trial in Stargardt patients (preliminary readout expected Q4 2022).

About Nanoscope Therapeutics Inc.
Nanoscope is developing optogenetic therapies to restore sight in the millions of IRD patients, for which no cure exists. Nanoscope’s pipeline includes therapies for RP, Stargardt, and dry age-related macular degeneration.

About BIO
BIO is the world’s largest biotechnology advocacy organization representing companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 countries. BIO members are involved in innovative healthcare R&D, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings globally.

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

DALLAS, Feb. 11, 2022  — Nanoscope Therapeutics Inc., today announced that CEO Sulagna Bhattacharya will present at the BIO CEO & Investor Conference, Tuesday, February 15 at 1:30 pm in the Empire Room at the Marriott Marquis in New York City.  BIO CEO & Investor Conference will be held there from February 14 – 17.  In addition to presenting, management will be available for virtual and in person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

Ms. Bhattacharya will update investors on the company’s proprietary Multi-Characteristic Opsin (MCO) gene therapy platform, which is in development for restoration of vision in patients blinded by inherited retinal degenerative diseases, such as retinitis pigmentosa (RP) and Stargardt macular degeneration, regardless of genetic mutations.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics has developed an optogenetic gene therapy platform to restore sight in the millions of blind patients suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes multiple late clinical stage optogenetic gene therapies assets for patients with RP, Stargardt Macular Degeneration, and dry age-related macular degeneration.  Nanoscope leverages a proprietary AAV2 vector to deliver MCO-010 (lead asset) as an optogenetic monotherapy that reprograms remaining healthy retinal cells to sense ambient light in patients that have lost their photoreceptors. The therapy involves a single intravitreal injection given in a medical office setting. MCO-010 has received orphan drug designations from the FDA for RP and Stargardt macular degeneration.

A Phase 2b multicenter, randomized, double-masked, sham controlled clinical trial for the company’s lead asset, MCO-010, is fully enrolled in the U.S. for treatment of RP (NCT04945772).  Results are expected in Q1 2023. In a prior Phase 1/2a open label trial of MCO-010, RP patients experienced restoration of vision to a level sufficient to resume activities of daily living.

Nanoscope also has received IND clearance from the FDA to begin a Phase 2 trial of MCO-010 to restore vision in Stargardt patients and is presently screening adolescent and adult patients for recruitment. This trial marks a significant step for the company’s MCO gene therapy platform towards Dry Age-Related Macular Degeneration (Dry-AMD) with results expected in H2 2022.

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

DALLAS, Feb. 7, 2022  — Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2b clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in patients with retinitis pigmentosa (RP). Topline results are expected in Q1 of next year.

“Completing enrollment for this trial is another important milestone for Nanoscope and millions suffering from retinal diseases for which there are no effective treatments,” said Sulagna Bhattacharya, CEO of Nanoscope. “Positive results from this trial will bring us closer to meeting this significant unmet medical need.”

A Completed Phase 1/2a study of MCO-010 in 11 patients with RP demonstrated that the optogenetic therapy was well-tolerated, with improved quality of life consistent with significant functional vision improvement in advanced RP patients.

The Phase 2b trial (NCT04945772) enrolled 27 participants with severe vision loss due to advanced RP in a randomized, double-masked, sham-controlled, multi-center trial. In this study, patients receive either an injection of MCO-010 or a sham injection to evaluate the efficacy and safety of MCO-010 therapy.

“RP is a progressive inherited condition caused by a spectrum of different gene mutations. This optogenetic therapy has the potential to impact patients with various genetic types of RP,” said Byron Lam, MD, Neuro-Ophthalmology Professor at Bascom Palmer Eye Institute and leading expert on RP.

Nanoscope’s optogenetic therapy uses a proprietary AAV2 vector to deliver MCO genes into retinal cells enabling vision in natural environments. The therapy is administered as a single eye injection for in-office delivery without the need for any other devices or interventions. Based on evidence from the Phase 1/2a study, MCO-010 is potentially applicable for vision restoration in retinal degenerative diseases irrespective of gene mutations. MCO-010 has received orphan drug designations for RP and Stargardt disease from the FDA. A Phase-2 study in Stargardt macular degeneration is also being initiated.

About RP 
RP, linked to over 100 different gene mutations, encompasses a group of rare disorders where photoreceptors degrade, leading to blindness in approximately 2 million individuals.

About Nanoscope Therapeutics
Nanoscope Therapeutics is developing optogenetic therapies to restore sight in millions of blind individuals suffering from retinal diseases, for which no cure exists. The pipeline includes optogenetic therapies for RP, Stargardt, and dry-AMD.

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

BEDFORD, Texas, Feb. 1, 2022  — Nanoscope Therapeutics Inc, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced an expansion of its Clinical and Scientific Advisory Board with the appointment of five new members.

“We are honored to have such distinguished experts in retinal disorders and gene therapy join us as advisers. The fact that top key opinion leaders are joining us speaks to how innovative our therapies are and how impactful they will be on patients’ lives,” said Nanoscope President and CSO, Samarendra Mohanty, Ph.D. “Their guidance will be invaluable as we advance our clinical development of gene therapies to restore vision in patients blinded by retinal diseases.”

New members include:

• David S. Boyer, M.D., Senior Partner, Retina-Vitreous Associates Medical Group in Southern California.
• Jeff Heier, M.D., Co-President and Medical Director, Ophthalmic Consultants of Boston and Assistant Professor, Ophthalmology, Tufts University School of Medicine
• Peter Kaiser, M.D., Director of the Center of Ocular Research and Evaluation, Cleveland Clinic’s Cole Eye Institute and Professor of Ophthalmology
• Stephen Kaminsky, Ph.D., Professor of Research in Genetic Medicine and Associate Director, Gene Therapy Core, Weill Cornell Medical College.
• Steven Gray, Ph.D., Associate Professor, University of Texas Southwestern Medical Center and Director of the Viral Vector Facility.

They join an existing group of distinguished advisory board members (SriniVas R. Sadda, M.D., Michael Singer, M.D., Stephen H. Tsang, M.D, Ph.D.; Vittorio Porciatti, D.Sc.; Paul Yang, M.D., Ph.D.; Thomas Yorio, Ph.D.; and Sai Chavala, M.D.), who are advising Nanoscope on inherited retinal disorders, macular degenerations, scientific affairs, and cell-gene therapies.

Nanoscope has received orphan drug designations from the U.S. Food and Drug Administration for Retinitis Pigmentosa (RP) and Stargardt disease. The company is conducting double-masked, sham-controlled, multisite Phase 2b clinical trials in the U.S. for RP and is expanding into macular degeneration with another multisite Phase 2 trial on Stargardt disease.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with RP, Stargardt disease, and other inherited retinal disorders as well as macular degenerations. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted gene therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/

Contact:

Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

BEDFORD, TX (January 25, 2022) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced it received IND clearance from the FDA to begin a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy to restore vision in Stargardt patients.

“This is another important milestone for Nanoscope, giving us the opportunity of conducting a second clinical trial in the U.S. of our proprietary MCO gene therapy platform, designed to restore vision for patients suffering from retinal degenerative diseases,” said Sulagna Bhattacharya, CEO of Nanoscope. “Currently there are no approved treatments for these conditions.”

This Phase 2 clinical trial for Stargardt is expected to begin in H1-2022. Nanoscope is currently conducting a Phase 2b multicenter, randomized, sham-controlled and double-masked study of MCO-010 for RP patients. MCO-010 has received orphan drug designations from the FDA for RP and Stargardt. Stargardt is a macular degeneration (MD) affecting children and adults. Progress on Nanoscope’s Stargardt program trial has implications for MCO as a platform and its impact beyond rare diseases.

“Presently all existing trials attempt to slow down the progression of vision loss in patients with Stargardt disease, Optogenetic approach is to restore vision. This can be a groundbreaking attempt to evaluate optogenetic gene therapy to improve vision in Stargardt patients. I’m excited by the potential MCO-010 has to restore vision for many patients with sight loss caused by outer retinal dystrophies including dry age-related macular degeneration”, said David S. Boyer, M.D., Retina-Vitreous Associates Medical Group and adjunct clinical professor of ophthalmology with Keck School of Medicine at the University of Southern California.

Stargardt is an inherited retinal disease involving dysfunction/degeneration of photoreceptors. Nanoscope’s MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive. It uses proprietary AAV2 vectors to deliver the MCO genes into the cells where they express polychromatic opsins enabling vision in different color environments. The therapy, involving a single intravitreal injection given in a medical office setting, is applicable for RP and Stargardt regardless of underlying gene mutations.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with RP, Stargardt, and dry age-related MD.

Contact:

Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

BEDFORD, Texas, Jan. 19, 2022 /– Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for the treatment of retinal degenerative diseases, will be featured in several presentations at BiOS, the world’s largest biomedical optics and biophotonics conference, as a part of SPIE Photonics West 2022, in San Francisco, January 22–27, 2022 at the Moscone Center.

“We are proud to be featured this year and look forward to highlighting our efforts to address retinal degenerative diseases with the goal of bringing relief to the millions of patients worldwide suffering from vision loss,” said Sulagna Bhattacharya, CEO of Nanoscope.

Nanoscope’s President and Chief Scientific Officer Samarendra Mohanty, Ph.D., is co-chair of Conference on Optogenetics and Optical Manipulation. The program will feature three presentations on Nanoscope’s technologies, including one by Dr. Mohanty titled Optogenetic Vision Restoration with Multi-Characteristic Opsins in Bipolar Cells, Jan. 23, 9:30 am, Rm 105 (Level 1 South Lobby).

In addition, Dr. Mohanty will present: Ultrafast Laser Based Transient Perforation of Cellular Membranes for In Vivo Neuromodulation, highlighting Nanoscope’s patented non-viral laser gene delivery technology. The presentation, Jan. 23, 2 pm, Rm 153 (Upper Mezzanine South), is part of the program on Frontiers in Ultrafast Optics: Biomedical, Scientific, and Industrial Applications XXII.

Nanoscope is also presenting:

• Spatially Targeted Non-Viral Optical Delivery of Opsin-Encoding Genes into Primate Retina, Jan. 22, 2 pm, Rm 105(Level 1 South Lobby), by Sanghoon Kim, Ph.D.
• Multi-characteristic opsin restores vision in Stargardt mice model, Jan. 22, 3:30 pm, Rm 105 (Level 1 South), by Subrata Batabyal, Ph.D.

Nanoscope’s lead product, MCO-010, is in multicenter, randomized, double-masked Phase 2b clinical trials in the U.S. for treatment of RP (NCT04945772). In a Phase 1/2a open label trial of MCO-010, RP patients experienced restoration of vision to a level sufficient to resume activities of daily living.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies to give sight to millions of patients suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetic monotherapy for patients with retinitis pigmentosa, Stargardt disease, and other IRDs as well as macular degenerations. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted MCO therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Bedford, TX, January 12, 2022 –  Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative diseases, today announced that it has been named winner in the “Biotech Innovation” category at the D CEO and Dallas Innovates third annual 2022 Innovation Awards, which honors disruptors and trailblazers contributing to the North Texas Hi-Tech corridor.

Nanoscope Therapeutics team accepting the 2022 Biotech Innovation Award. From left: Anthony Togba, CFO; Sulagna Bhattacharya, Co-Founder and CEO; and Samarendra Mohanty, Co-Founder and President.

In accepting the award, Nanoscope Co-Founder and CEO Sulagna Bhattacharya stated, “A big thanks to the hard-working and talented team at Nanoscope. I am also thankful to Dallas Innovates and D CEO magazine for their support of the Biotech industry and for recognizing companies like ours, focused on finding cures for previously-untreatable diseases. This award highlights the potential of our gene therapy to address unmet medical needs for millions of patients with retinal diseases around the world”.

Nanoscope’s proprietary Multi-Characteristic Opsin (MCO) gene therapy platform is in late-stage clinical development for restoration of vision in patients blinded by retinal degenerative diseases, such as retinitis pigmentosa (RP), regardless of genetic mutations and type of retinal degenerative disease.

“Biotech Innovation requires passion and perseverance. When we started 12 years back, gene therapy held promise and hope. Now, in this exciting era of gene therapy, we are on the cusp of bringing restorative therapy for blindness caused by retinal degenerative diseases,” said Samarendra Mohanty, Co-Founder and President of Nanoscope.

The company’s lead product, MCO-010, is in a Phase 2b multicenter, randomized, double-masked, sham controlled clinical trial in the US for treatment of RP (NCT04945772), and is expanding into macular degeneration with another Phase 2 trial on Stargardt disease. In a Phase 1/2a trial of MCO-010, all 11 RP patients experienced restoration of vision to a level sufficient to resume activities of daily living. Nanoscope has received orphan drug designation from the U.S. FDA for RP and Stargardt disease.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with retinitis pigmentosa, Stargardt disease, and other IRDs as well as macular degenerations. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted MCO therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

BEDFORD, Texas, Jan 10, 2022 — Nanoscope Therapeutics Inc, a clinical-stage biotechnology company developing optogenetic gene therapies for retinal degenerative diseases, today announced that Nanoscope has been awarded U.S. patent 11,180,537 covering its Multi-Characteristic Opsin (MCO) optogenetic gene therapy platform for restoring vision. This award bolsters Nanoscope’s existing intellectual property position on composition and methods for the MCO therapeutics in Australia (AU2017372351) and Japan (JP6779546).

“This foundational patent with protection through 2037 is another milestone for Nanoscope and our efforts to bring the hope of light to people suffering from retinal diseases by enabling them to see again and regain their quality of life,” said Sulagna Battacharya, CEO of Nanoscope.

The patent, titled “Optogenetic modulation by Multi-Characteristic Opsins for vision restoration and other applications,” from the USPTO provides broad protections for MCO, and their therapeutic applications.

Nanoscope aims to treat retinal diseases such as retinitis pigmentosa (RP) and macular degenerations with MCO gene therapy, regardless of genetic mutations. MCO therapy is used to reprogram surviving retinal cells to sense light again in real-world conditions. MCO’s unique mechanism of action restores fast, broadband, and ambient-light sensitivity, thus allowing vision restoration in different natural and recreational situations without use of external light stimulation devices such as goggles.

“This patent represents one of over half a dozen patents awarded for our innovations on optogenetic molecules, and methods of delivery/treatment. Our mission is to develop therapies that restores light sensitivity under everyday circumstances. Our proprietary technology provides a competitive advantage as we bring first-in-class therapies to market towards that mission,” said Samarendra Mohanty, MCO-platform Inventor and President of Nanoscope.

The company is conducting double-masked, sham-controlled, multisite Phase 2b clinical trials in the U.S. for RP and is expanding into macular degeneration with another Phase 2 trial on Stargardt disease. It has received orphan drug designation from the U.S. Food and Drug Administration for RP and Stargardt disease.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with RP, Stargardt disease, and other retinal disorders. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted MCO therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

Bedford, TX,  December 22, 2021 –  Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative diseases, has been named a finalist for the D CEO and Dallas Innovates third annual Innovation Awards, which recognize companies that contribute to making Dallas-Fort Worth an innovation hub.

“We are proud to be part of the Dallas-Fort Worth biotech community and we greatly appreciate that D CEO and Dallas Innovates recognize our team’s efforts to develop a new treatment – a first-of-its kind gene therapy – to restore vision in patients blinded by retinal diseases,” said Nanoscope Co-Founder and CEO Sulagna Battacharya.

The 2022 Innovation Awards honor companies as well as business executives, entrepreneurs, and other leaders. Nanoscope was named a finalist in the category of Innovation in Biotech. All finalists will be recognized in the January/February issue of D CEO magazine and online at DallasInnovates.com. Winners will be revealed at an exclusive awards event in January.

Nanoscope’s proprietary Multi-Characteristic Opsin (MCO) gene therapy platform is being developed for restoration of vision in patients blinded by retinal degenerative diseases, such as retinitis pigmentosa (RP), regardless of genetic mutations.

The company’s lead product, MCO-010, is in a Phase 2b multicenter, randomized, double-masked, sham controlled clinical trial in the U.S. for treatment of RP (NCT04945772). Results are expected in Q4 2022. In a Phase 1/2a open label trial of MCO-010, all 11 RP patients experienced restoration of vision to a level sufficient to resume activities of daily living.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with retinitis pigmentosa, Stargardt disease, and other IRDs as well as macular degenerations. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted MCO therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

BEDFORD, Texas, Dec. 8, 2021 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative diseases, announced today the company’s Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation by Michael Singer, M.D., a member of Nanoscope’s Clinical Advisory Board, at Stanford University’s Innovate Retina summit on December 11, 2021

Dr. Singer is Clinical Professor of Ophthalmology at the University of Texas Health Science Center in San Antonio, Texas, and Director of Clinical Research at Medical Center Ophthalmology Associates in San Antonio. His presentation is part of a program titled “Global Innovation in Retina” organized by Stanford University School of Medicine’s Byers Eye Institute. Online registration is free.

Nanoscope’s MCO optogenetic gene therapy is in clinical development for vision restoration in people blinded by retinitis pigmentosa (RP) regardless of genetic mutations. Nanoscope is conducting a multicenter Phase 2b trial in the U.S. (NCT04945772). Results are expected in Q4 2022. In a Phase 1/2a trial, the RP patients experienced restoration of vision to a level sufficient to resume activities of daily living.

“I am very thrilled about the potential for this new therapy for patients with retinitis pigmentosa,” Dr. Singer said. “The prospect of visual restoration in these nearly blind patients is incredibly exciting.”

Dr. Singer’s presentation, titled “Nanoscope Therapeutics: Introduction and Perspectives,” begins at 8:42 am Pacific Standard Time followed by his participation in a panel discussion.

“We are pleased Dr. Singer is presenting our unique MCO platform aimed at helping millions of people worldwide who suffer from retinal diseases,” said Sulagna Battacharya, CEO of Nanoscope. “Dr. Singer has been instrumental in advising the company as its advances its clinical development programs not only in RP, but also for Stargardt disease and age-related macular degeneration.”

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with retinitis pigmentosa, Stargardt disease, and other inherited retinal disorders as well as macular degenerations. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted MCO therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716

BEDFORD, Texas, Dec. 3, 2021 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for treatment of retinal degenerative diseases, was awarded as the Top Retina Company at the Eyecelerator conference at the 2021 meeting of the American Academy of Ophthalmology (AAO) in New Orleans, LA.

Nanoscope won top company honors in the retina innovation category for exciting development of proprietary Multi-Characteristic Opsin (MCO) gene therapy platform for restoring vision in patients blinded by retinal degenerative diseases, such as retinitis pigmentosa (RP), regardless of genetic mutations. The technology was featured in a presentation by Samarendra Mohanty, Ph.D., Nanoscope Co-Founder and President.

“Nanoscope was recognized as an up-and-coming company with an innovative optogenetic gene therapy that may offer a different approach to treating retinal diseases,” said Allen C. Ho, MD, Attending Surgeon and Director of Retina Research Wills Eye Hospital and Eyecelerator program Co-chair.

The Eyecelerator conference is organized by AAO and the American Society of Cataract and Refractive Surgery to showcase emerging technology, groundbreaking research and inventive concepts in ophthalmology.

“We thank the organizers for recognizing our progress in development of a unique gene therapy to restore meaningful vision for the millions of people worldwide who are blinded by retinal degenerative diseases,” said Sulagna Bhattacharya, CEO of Nanoscope.

Nanoscope’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for treatment of RP (NCT04945772). In Phase 1/2a trial of MCO-010, the RP patients experienced restoration of vision to a level sufficient to independently resume everyday activities.

The company’s MCO gene therapy has a unique mechanism of action and characteristics of being fast, broadband, and ambient-light sensitive allowing vision restoration in everyday settings. MCO-010 has received orphan drug designations from the FDA for RP and Stargardt disease.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing optogenetic therapies for giving sight to the millions of blind individuals suffering from retinal degenerative diseases, for which no cure exists. The company’s pipeline includes optogenetics based retinal regeneration therapy for patients with inherited retinal disorders as well as macular degenerations. Nanoscope is also advancing a proprietary non-viral laser gene delivery platform for targeted MCO therapy of geographic atrophies. For more information visit: https://nanostherapeutics.com/

Contact:
Dan Eramian
Opus Biotech Communications
pr@nanostherapeutics.com
425-306-8716